Cargando…

Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning

One of the main problems in the treatment of poisoning with organophosphorus (OPs) inhibitors of acetylcholinesterase (AChE) is low ability of existing reactivators of AChE that are used as antidotes to cross the blood-brain barrier (BBB). In this work, modified cationic liposomes were developed tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuznetsova, Darya A., Gaynanova, Gulnara A., Vasilieva, Elmira A., Pavlov, Rais V., Zueva, Irina V., Babaev, Vasily M., Kuznetsov, Denis M., Voloshina, Alexandra D., Petrov, Konstantin A., Zakharova, Lucia Y., Sinyashin, Oleg G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506492/
https://www.ncbi.nlm.nih.gov/pubmed/36145698
http://dx.doi.org/10.3390/pharmaceutics14091950
_version_ 1784796736439451648
author Kuznetsova, Darya A.
Gaynanova, Gulnara A.
Vasilieva, Elmira A.
Pavlov, Rais V.
Zueva, Irina V.
Babaev, Vasily M.
Kuznetsov, Denis M.
Voloshina, Alexandra D.
Petrov, Konstantin A.
Zakharova, Lucia Y.
Sinyashin, Oleg G.
author_facet Kuznetsova, Darya A.
Gaynanova, Gulnara A.
Vasilieva, Elmira A.
Pavlov, Rais V.
Zueva, Irina V.
Babaev, Vasily M.
Kuznetsov, Denis M.
Voloshina, Alexandra D.
Petrov, Konstantin A.
Zakharova, Lucia Y.
Sinyashin, Oleg G.
author_sort Kuznetsova, Darya A.
collection PubMed
description One of the main problems in the treatment of poisoning with organophosphorus (OPs) inhibitors of acetylcholinesterase (AChE) is low ability of existing reactivators of AChE that are used as antidotes to cross the blood-brain barrier (BBB). In this work, modified cationic liposomes were developed that can penetrate through the BBB and deliver the reactivator of AChE pralidoxime chloride (2-PAM) into the brain. Liposomes were obtained on the basis of phosphatidylcholine and imidazolium surfactants. To obtain the composition optimized in terms of charge, stability, and toxicity, the molar ratio of surfactant/lipid was varied. For the systems, physicochemical parameters, release profiles of the substrates (rhodamine B, 2-PAM), hemolytic activity and ability to cause hemagglutination were evaluated. Screening of liposome penetration through the BBB, analysis of 2-PAM pharmacokinetics, and in vivo AChE reactivation showed that modified liposomes readily pass into the brain and reactivate brain AChE in rats poisoned with paraoxon (POX) by 25%. For the first time, an assessment was made of the ability of imidazolium liposomes loaded with 2-PAM to reduce the death of neurons in the brains of mice. It was shown that intravenous administration of liposomal 2-PAM can significantly reduce POX-induced neuronal death in the hippocampus.
format Online
Article
Text
id pubmed-9506492
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95064922022-09-24 Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning Kuznetsova, Darya A. Gaynanova, Gulnara A. Vasilieva, Elmira A. Pavlov, Rais V. Zueva, Irina V. Babaev, Vasily M. Kuznetsov, Denis M. Voloshina, Alexandra D. Petrov, Konstantin A. Zakharova, Lucia Y. Sinyashin, Oleg G. Pharmaceutics Article One of the main problems in the treatment of poisoning with organophosphorus (OPs) inhibitors of acetylcholinesterase (AChE) is low ability of existing reactivators of AChE that are used as antidotes to cross the blood-brain barrier (BBB). In this work, modified cationic liposomes were developed that can penetrate through the BBB and deliver the reactivator of AChE pralidoxime chloride (2-PAM) into the brain. Liposomes were obtained on the basis of phosphatidylcholine and imidazolium surfactants. To obtain the composition optimized in terms of charge, stability, and toxicity, the molar ratio of surfactant/lipid was varied. For the systems, physicochemical parameters, release profiles of the substrates (rhodamine B, 2-PAM), hemolytic activity and ability to cause hemagglutination were evaluated. Screening of liposome penetration through the BBB, analysis of 2-PAM pharmacokinetics, and in vivo AChE reactivation showed that modified liposomes readily pass into the brain and reactivate brain AChE in rats poisoned with paraoxon (POX) by 25%. For the first time, an assessment was made of the ability of imidazolium liposomes loaded with 2-PAM to reduce the death of neurons in the brains of mice. It was shown that intravenous administration of liposomal 2-PAM can significantly reduce POX-induced neuronal death in the hippocampus. MDPI 2022-09-15 /pmc/articles/PMC9506492/ /pubmed/36145698 http://dx.doi.org/10.3390/pharmaceutics14091950 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kuznetsova, Darya A.
Gaynanova, Gulnara A.
Vasilieva, Elmira A.
Pavlov, Rais V.
Zueva, Irina V.
Babaev, Vasily M.
Kuznetsov, Denis M.
Voloshina, Alexandra D.
Petrov, Konstantin A.
Zakharova, Lucia Y.
Sinyashin, Oleg G.
Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning
title Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning
title_full Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning
title_fullStr Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning
title_full_unstemmed Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning
title_short Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning
title_sort oxime therapy for brain ache reactivation and neuroprotection after organophosphate poisoning
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506492/
https://www.ncbi.nlm.nih.gov/pubmed/36145698
http://dx.doi.org/10.3390/pharmaceutics14091950
work_keys_str_mv AT kuznetsovadaryaa oximetherapyforbrainachereactivationandneuroprotectionafterorganophosphatepoisoning
AT gaynanovagulnaraa oximetherapyforbrainachereactivationandneuroprotectionafterorganophosphatepoisoning
AT vasilievaelmiraa oximetherapyforbrainachereactivationandneuroprotectionafterorganophosphatepoisoning
AT pavlovraisv oximetherapyforbrainachereactivationandneuroprotectionafterorganophosphatepoisoning
AT zuevairinav oximetherapyforbrainachereactivationandneuroprotectionafterorganophosphatepoisoning
AT babaevvasilym oximetherapyforbrainachereactivationandneuroprotectionafterorganophosphatepoisoning
AT kuznetsovdenism oximetherapyforbrainachereactivationandneuroprotectionafterorganophosphatepoisoning
AT voloshinaalexandrad oximetherapyforbrainachereactivationandneuroprotectionafterorganophosphatepoisoning
AT petrovkonstantina oximetherapyforbrainachereactivationandneuroprotectionafterorganophosphatepoisoning
AT zakharovaluciay oximetherapyforbrainachereactivationandneuroprotectionafterorganophosphatepoisoning
AT sinyashinolegg oximetherapyforbrainachereactivationandneuroprotectionafterorganophosphatepoisoning